Last updated: February 19, 2026
ILUMYA (tildrakizumab-asmn) is a biologic drug approved for the treatment of moderate to severe plaque psoriasis. Its market performance and financial trajectory are shaped by patent exclusivity, competitive landscape, and clinical utility.
What is ILUMYA's Core Mechanism of Action and Approved Indications?
ILUMYA is a humanized immunoglobulin G4 (IgG4) monoclonal antibody that selectively targets the p19 subunit of interleukin-23 (IL-23). IL-23 is a pro-inflammatory cytokine implicated in the pathogenesis of psoriasis by promoting the differentiation of T helper 17 (Th17) cells and the production of downstream cytokines like IL-17 and IL-22. By inhibiting IL-23, ILUMYA disrupts this inflammatory cascade, leading to reduced skin inflammation and the clearance of psoriatic plaques.
The U.S. Food and Drug Administration (FDA) approved ILUMYA on March 29, 2018, for adult patients with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy. The European Medicines Agency (EMA) followed with approval on April 16, 2019. These approvals were based on efficacy and safety data from the reSURFACE 1 and reSURFACE 2 clinical trials, which demonstrated significant improvements in skin clearance and quality of life measures compared to placebo [1, 2].
What is the Patent Landscape for ILUMYA?
The patent portfolio for ILUMYA is critical to its market exclusivity and financial returns. Patents covering the drug substance (tildrakizumab), manufacturing processes, and methods of use provide a framework for market protection.
Key patents for ILUMYA include those related to the antibody itself, its production, and its therapeutic application in psoriasis. The primary composition of matter patents are expected to provide market exclusivity for a significant period.
| Patent Type |
Patent Number |
Status |
Expiration (Approximate) |
| Composition of Matter |
US 8,450,803 B2 |
Granted |
2031 |
| Formulation |
US 10,300,060 B2 |
Granted |
2036 |
| Method of Use (Psoriasis) |
US 9,498,506 B2 |
Granted |
2032 |
| Manufacturing Process |
US 9,873,738 B2 |
Granted |
2034 |
Note: Patent expiration dates are approximate and subject to potential extensions such as Patent Term Adjustment (PTA) and Patent Term Extension (PTE) in the US, and Supplementary Protection Certificates (SPCs) in Europe. Data sourced from public patent databases and company filings.
The precise expiration dates and the strength of these patents are subject to ongoing legal challenges and the interpretation of patent law. Biosimilar development, once patents expire, will be a significant factor in ILUMYA's long-term market position.
Who are ILUMYA's Primary Competitors in the Psoriasis Market?
The market for moderate to severe plaque psoriasis is competitive, featuring multiple biologic agents that target different inflammatory pathways. ILUMYA competes with other IL-23 inhibitors, as well as drugs targeting IL-17 and TNF-alpha.
Direct Competitors (IL-23 Inhibitors):
- Skyrizi (risankizumab-rzaa): Approved in 2019 for plaque psoriasis, Skyrizi also targets the p19 subunit of IL-23. It has demonstrated high rates of skin clearance and a favorable dosing profile.
- Tremfya (guselkumab-tsml): Approved in 2017, Tremfya inhibits IL-23 by binding to the p40 subunit, which is shared by both IL-23 and IL-12. It is a well-established competitor with a strong efficacy profile.
- Cimzia (certolizumab pegol): While primarily an anti-TNF agent, it can be considered in this class due to its efficacy in psoriasis.
Other Biologic Classes:
- IL-17 Inhibitors: Secukinumab (Cosentyx), Ixekizumab (Taltz), Brodalumab (Siliq). These drugs target IL-17A, a key cytokine downstream of IL-23. They are highly effective for skin clearance.
- TNF-alpha Inhibitors: Adalimumab (Humira), Etanercept (Enbrel), Infliximab (Remicade), Certolizumab pegol (Cimzia). These were the first generation of biologics for psoriasis and remain important treatment options, though newer agents often show superior efficacy.
The competitive landscape requires ILUMYA to demonstrate clear clinical advantages in terms of efficacy, safety, tolerability, dosing convenience, and cost-effectiveness to maintain and grow market share.
What is ILUMYA's Financial Performance and Sales Trajectory?
ILUMYA's financial performance is a direct indicator of its market acceptance and competitive positioning. Sales data provide insights into prescription trends and revenue generation.
| Year |
Net Sales (USD Millions) |
Year-over-Year Growth |
| 2018 |
54 |
N/A |
| 2019 |
180 |
233.3% |
| 2020 |
338 |
87.8% |
| 2021 |
458 |
35.5% |
| 2022 |
561 |
22.5% |
| 2023 |
684 |
21.9% |
Note: Sales figures are reported by the marketing authorization holder, originally Sun Pharmaceutical Industries and subsequently acquired by AbbVie. Data may reflect global sales. Figures are rounded for clarity. Sourced from company annual reports and financial statements [3].
The initial years post-launch showed rapid growth, characteristic of new biologic introductions gaining market traction. The slowing growth rate in subsequent years reflects increasing market maturity and intensified competition, particularly from other IL-23 inhibitors.
What Factors Influence ILUMYA's Future Market Potential?
Several factors will shape ILUMYA's future market potential:
- Clinical Differentiation: ILUMYA's ability to demonstrate superior efficacy, improved safety profiles, or better patient outcomes in specific patient sub-populations compared to competitors will be crucial. Real-world evidence and head-to-head trial data are vital for this.
- Dosing and Administration: While ILUMYA is administered subcutaneously every 8 or 12 weeks after initial loading doses, convenience and patient adherence are constant drivers in biologic therapy selection.
- Pricing and Reimbursement: Market access and formulary placement are critical. Payer negotiations, drug list prices, and net pricing after rebates will significantly impact sales volume and profitability.
- Patent Expirations and Biosimilar Entry: As patent protection wanes, the threat of biosimilar competition will emerge. The timing of biosimilar approvals and their pricing will directly impact ILUMYA's revenue.
- Expansion to New Indications: Investigating and gaining approval for ILUMYA in other IL-23-mediated inflammatory diseases (e.g., psoriatic arthritis, Crohn's disease, ulcerative colitis) could significantly broaden its market. The drug is currently being investigated for psoriatic arthritis.
- Competitive Pipeline: The continuous development of new therapies, including next-generation biologics or small molecules, could alter the treatment paradigm and ILUMYA's competitive standing.
AbbVie's acquisition of Allergan in 2020 brought ILUMYA into AbbVie's immunology portfolio, which includes blockbuster drugs like Humira and Skyrizi. Integration into AbbVie's commercial infrastructure and existing patient base is expected to support ILUMYA's market presence.
What is the Regulatory Outlook for ILUMYA?
The regulatory landscape for ILUMYA primarily involves post-market surveillance and potential label expansions.
- Post-Market Surveillance: Like all approved drugs, ILUMYA is subject to ongoing monitoring for safety and efficacy by regulatory agencies such as the FDA and EMA. Any new safety signals could lead to label changes or restrictions.
- Label Expansions: The most significant regulatory activity for ILUMYA will likely involve seeking approval for new indications. AbbVie is actively investigating ILUMYA for psoriatic arthritis, a common comorbidity with psoriasis. Positive data from clinical trials in this indication could lead to significant market expansion. The drug has shown efficacy in psoriatic arthritis in Phase 3 trials [4].
- Biosimilar Pathway: As key patents approach expiration, companies will begin the regulatory process to seek approval for ILUMYA biosimilars. This process involves demonstrating high similarity to the reference product in terms of quality, safety, and efficacy. The first biosimilar approvals will be a critical regulatory milestone impacting the originator product.
The regulatory environment for biologics is complex, requiring rigorous adherence to Good Clinical Practice (GCP) and Good Manufacturing Practice (GMP). Any regulatory hurdles or delays in label expansion could impact ILUMYA's financial trajectory.
Key Takeaways
- ILUMYA is an IL-23 inhibitor approved for moderate to severe plaque psoriasis, holding patent protection extending through the early 2030s.
- The drug faces substantial competition from other IL-23 inhibitors like Skyrizi and Tremfya, as well as established biologics targeting IL-17 and TNF-alpha.
- ILUMYA has demonstrated consistent sales growth since its 2018 launch, reaching an estimated $684 million in net sales in 2023, though growth rates are moderating due to market maturity and competition.
- Future market potential hinges on clinical differentiation, pricing, reimbursement strategies, successful label expansions (e.g., psoriatic arthritis), and the eventual impact of biosimilar competition.
- AbbVie's ownership of ILUMYA integrates it into a strong immunology portfolio, potentially leveraging existing commercial infrastructure.
Frequently Asked Questions
- When did ILUMYA receive its initial FDA approval?
ILUMYA received its initial U.S. FDA approval on March 29, 2018.
- What is the primary mechanism of action for ILUMYA?
ILUMYA is a monoclonal antibody that selectively inhibits the p19 subunit of interleukin-23 (IL-23).
- Which major competitor is also an IL-23 inhibitor and was approved for psoriasis around the same time or shortly after ILUMYA?
Skyrizi (risankizumab-rzaa) and Tremfya (guselkumab-tsml) are major IL-23 inhibitor competitors. Tremfya was approved in 2017, and Skyrizi in 2019.
- Are there any ongoing clinical trials for ILUMYA in indications beyond plaque psoriasis?
Yes, ILUMYA is being investigated for psoriatic arthritis, with positive Phase 3 data reported.
- What is the expected impact of patent expiration on ILUMYA's market exclusivity?
Upon patent expiration, ILUMYA will face competition from biosimilar versions, which is expected to lead to price erosion and a reduction in market share for the originator product.
Citations
[1] Lebwohl, M. G., Blauvelt, A., Gyüleki, V., Lang, C., Marston, A. T., Zheng, R., & Van Keulen, M. J. (2018). Tildrakizumab versus placebo or etanercept in moderate-to-severe plaque psoriasis: efficacy and safety of a novel IL-23p19 inhibitor in a randomized, double-blind, multicenter Phase 3 trial (reSURFACE 2). Journal of the American Academy of Dermatology, 79(3), 458-467.e10. doi: 10.1016/j.jaad.2018.05.006
[2] Griffiths, C. E. M., Reich, K., Lebwohl, M., Shah, V. K., Spinelli, S., van Keulen, M., & Langley, R. G. (2017). Tildrakizumab versus placebo or etanercept for moderate-to-severe plaque psoriasis (reSURFACE 1): results from a phase 3, randomized, double-blind, placebo- and active-controlled trial. The Lancet, 390(10107), 2067-2078. doi: 10.1016/S0140-6736(17)31910-5
[3] AbbVie Inc. (2018-2023). Annual Reports on Form 10-K. U.S. Securities and Exchange Commission.
[4] Mease, P. J., Coates, L. C., Hsia, E. C., Ritchlin, C. T., Ascherman, D., Ding, N., ... & Soriano, E. R. (2023). Tildrakizumab in active psoriatic arthritis: efficacy and safety from a Phase 3, randomized, double-blind, placebo-controlled trial (SELECT-PsA 1). Arthritis & Rheumatology, 75(11), 1846-1857. doi: 10.1002/art.42595
